Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $10.8 million.

  • Fulcrum Therapeutics' Non-Current Assets fell 21.91% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 21.91%. This contributed to the annual value of $10.8 million for FY2024, which is 30.33% down from last year.
  • Fulcrum Therapeutics' Non-Current Assets amounted to $10.8 million in FY2024, which was down 30.33% from $15.5 million recorded in FY2023.
  • Fulcrum Therapeutics' 5-year Non-Current Assets high stood at $19.2 million for FY2022, and its period low was $9.0 million during FY2021.
  • For the 3-year period, Fulcrum Therapeutics' Non-Current Assets averaged around $15.2 million, with its median value being $15.5 million (2023).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Non-Current Assets skyrocketed by 112.91% in 2022, and later crashed by 30.33% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Non-Current Assets stood at $10.1 million in 2020, then decreased by 10.58% to $9.0 million in 2021, then soared by 112.91% to $19.2 million in 2022, then declined by 19.15% to $15.5 million in 2023, then crashed by 30.33% to $10.8 million in 2024.